IMR Press / FBL / Volume 20 / Issue 1 / DOI: 10.2741/4300

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
MicroRNAs in human glioblastoma: from bench to beside
Show Less
1 Department of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2015, 20(1), 105–118; https://doi.org/10.2741/4300
Published: 1 January 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

Glioblastoma (GBM) is the most common and malignant adult primary brain tumor and one of the most lethal types of all cancers. Currently, despite interventional therapy (e.g. multimodal treatments with surgery, radiotherapy and chemotherapy), the overall prognosis for GBM patients remains poor. Thus, it is necessary to understand the molecular pathogenesis of GBM, which provides new insight into modern therapy. As a novel molecule, microRNA (miRNA) contributes to the pathogenesis of various types of tumor, including GBM. So far, miRNA has been shown to function in regulating protein-coding gene expression. This allows miRNAs to have direct function in regulation of various cellular events, including cell proliferation, apoptosis, and differentiation. Great progress has been made in identifying novel tumor-related miRNAs and their potential target genes. In this review, we focus on the most current research in miRNAs and their role in GBM regulation. In addition, we summarize some miRNAs found as biomarkers in GBM and their role in treatment.

Keywords
miRNA
Glioblastoma
Biogenesis
Signaling Pathway
Therapy
Review
Share
Back to top